New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2013
10:10 EDTROSGRosetta Genomics surges after announcing study publication
Shares of Rosetta Genomics (ROSG), which develops and commercializes microRNA-based molecular diagnostics, advanced in early trading after the company announced the recent publication of data from a study assessing the differences between cancer of unknown primary, or CUP, and metastatic solid tumors of known primary metastases, or KPM, by profiling microRNA expression. According to the company's press release, the study's author, George Pentheroudakis, said, "This research is the first look for microRNA characteristics of CUP tumors. Study results confirmed epidemiologic evidence suggesting that patients with favorable prognosis CUP have a presentation, response to therapy and outcome no different from metastatic tumors of matched primaries." The company's CEO said, "This publication demonstrates the utility of microRNA profiling in understanding the biology of CUP and may have important implications for the prognosis and treatment of CUP patients," adding that the company looks forward to the publication of the full data set. The company offered a link to an abstract of the study, which had an e-publication date of Nov. 4, 2012 ahead of its print publication, according to the post on the site of the U.S. National Library of Medicine and National Institutes of Health. In early morning trading, Rosetta Genomics shares rose $1.02, or 22.05% to $5.62. Reference Link
News For ROSG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
08:28 EDTROSGRosetta Genomics announces results for microRNA thyroid assay
Subscribe for More Information
February 18, 2015
09:33 EDTROSGRosetta Genomics enters $14.4M controlled equity offering sales agreement
Subscribe for More Information
February 17, 2015
08:19 EDTROSGRosetta Genomics announces U.S., European patent allowances for microRNA
Rosetta Genomics announced that the company received a Notice of Allowance from the United States Patent and Trademark Office for a patent claiming the use of miR-34a for the treatment of p53-associated cancers. In addition, the company announced its first allowance from the European Patent Office for a patent claiming the specific composition for miR-451, a miR relating to the company’s Cancer of Unknown Primary testing franchise. The allowed claims for the U.S. patent cover a core element of Rosetta Genomics’ microRNA technology in the development of cancer therapeutics relating to cancers associated with the p53 gene. This patent is broader than the previous patent issued last year in that it covers the treatment of any p-53 associated cancer using miR-34a or its variants, delivered by any kind of formulation. The patent is jointly owned with Yeda Research and Development. The allowed claims for the European patent cover miR-451 and its complement, as well as a probe comprising the claimed miR. Therapeutic and diagnostic uses of the miR and/or the probe are also covered in the allowed claims.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use